Team-science is essential to moving therapies forward. We first have to understand changes that occur with disease progression, and then we can ask how therapies change this course and promote tolerance. We work with scientists and clinicians with a range of expertise to assess the phenotype and function of immune cells in natural history and clincial trial settings with a focus on single cell technologies.
We have found that tolerogenic therapies can modulate the number, type and function of CD4 Treg or CD8 exhausted T cells. However, specific changes that associate with better outcome and how tolerance is conferred remain poorly understood. We are exploring these mechanisms across therapeutic modalities and autoimmune diseases.
